Nathalie Bleyzac


Ontology type: schema:Person     


Person Info

NAME

Nathalie

SURNAME

Bleyzac

Publications in SciGraph latest 50 shown

  • 2020-09-29 No time for pending confirmation of invasive fungal disease in critically ill COVID-19 patients—think empirical treatment in CRITICAL CARE
  • 2020-08-10 Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? in CLINICAL DRUG INVESTIGATION
  • 2020-06-12 A decision support tool to find the best cyclosporine dose when switching from intravenous to oral route in pediatric stem cell transplant patients in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2020-06-12 Azithromycin for COVID-19: More Than Just an Antimicrobial? in CLINICAL DRUG INVESTIGATION
  • 2020-03-11 Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children in CLINICAL PHARMACOKINETICS
  • 2020-02-10 Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial) in TRIALS
  • 2019-12-16 Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8 in CLINICAL PHARMACOKINETICS
  • 2018-09-08 A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4 in CLINICAL PHARMACOKINETICS
  • 2018-08-14 Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children in BONE MARROW TRANSPLANTATION
  • 2018-03-23 Identification of Cytochrome P450-Mediated Drug–Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model in CLINICAL PHARMACOKINETICS
  • 2018-02-05 Bayesian Networks: A New Approach to Predict Therapeutic Range Achievement of Initial Cyclosporine Blood Concentration After Pediatric Hematopoietic Stem Cell Transplantation in DRUGS IN R&D
  • 2017-09-09 Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism in CLINICAL PHARMACOKINETICS
  • 2016-12-06 A Model for Predicting the Interindividual Variability of Drug-Drug Interactions in THE AAPS JOURNAL
  • 2016-09-01 A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics in CLINICAL PHARMACOKINETICS
  • 2016-01-25 Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis in BONE MARROW TRANSPLANTATION
  • 2015-09-21 Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children in BONE MARROW TRANSPLANTATION
  • 2015-05-15 Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children in THE AAPS JOURNAL
  • 2013-01-15 In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates in THE AAPS JOURNAL
  • 2010-10-21 Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model in PHARMACEUTICAL RESEARCH
  • 2010-09-02 Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model in PHARMACEUTICAL RESEARCH
  • 2006-10-02 Human herpes virus-6 encephalitis in a paediatric bone marrow recipient: successful treatment with pharmacokinetic monitoring and high doses of ganciclovir in BONE MARROW TRANSPLANTATION
  • 2004-09-06 Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in BONE MARROW TRANSPLANTATION
  • 2004 Optimizing Individualized Dosage Regimens of Potentially Toxic Drugs in APPLICATIONS OF PHARMACOKINETIC PRINCIPLES IN DRUG DEVELOPMENT
  • 2003-10-16 Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors in BONE MARROW TRANSPLANTATION
  • 2003-10-01 Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors in BONE MARROW TRANSPLANTATION
  • 2003-06-01 Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources in BONE MARROW TRANSPLANTATION
  • 2001-10-01 Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens in BONE MARROW TRANSPLANTATION
  • 2001-09 Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2001-07 Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1999-05 Control of Intra and Inter-Patient Variability by Bayesian Forecasting of Busulfan Dosage Regimens in Pediatric BMT in PEDIATRIC RESEARCH
  • 1999-05 Low Dosing of Sandimmun® and Neoral® When Switching IV-PO Cyclosporin in Pediatric Bone Marrow Transplantation in PEDIATRIC RESEARCH
  • 1999-05 Medicoeconomic Evaluation of Granulocyte Colony Stimulating Factor (G-Csf) in Children Undergoing Allogeneic Bone Marrow Transplantation (Bmt) in PEDIATRIC RESEARCH
  • 1998-04 Individualization of Amikacin (AMK) Therapy in Neonates (NN) less than 2-day old 1421 in PEDIATRIC RESEARCH
  • 1995 Ganciclovir Nucleotide Analysis in Human Myocardial Tissue. Usefulness in the Diagnosis of Cytomegalovirus Myocarditis in PURINE AND PYRIMIDINE METABOLISM IN MAN VIII
  • 1994-01 Clinical use of ganciclovir during renal failure and continuous hemodialysis in INTENSIVE CARE MEDICINE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.413852.9", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.42505.36", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.462854.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413945.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414103.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413858.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411430.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.25697.3f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.239546.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413306.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.452431.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7849.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413959.3", 
            "type": "Organization"
          }
        ], 
        "familyName": "Bleyzac", 
        "givenName": "Nathalie", 
        "id": "sg:person.01250741512.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250741512.98"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-11-24T21:37", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/person/person_90.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01250741512.98'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01250741512.98'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01250741512.98'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01250741512.98'


     

    This table displays all metadata directly associated to this object as RDF triples.

    40 TRIPLES      10 PREDICATES      23 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01250741512.98 schema:affiliation N1946e8c0ade64daca38783683d6ee6c4
    2 grid-institutes:grid.239546.f
    3 grid-institutes:grid.25697.3f
    4 grid-institutes:grid.411430.3
    5 grid-institutes:grid.413306.3
    6 grid-institutes:grid.413858.3
    7 grid-institutes:grid.413945.e
    8 grid-institutes:grid.413959.3
    9 grid-institutes:grid.414103.3
    10 grid-institutes:grid.42505.36
    11 grid-institutes:grid.452431.5
    12 grid-institutes:grid.462854.9
    13 grid-institutes:grid.7849.2
    14 schema:familyName Bleyzac
    15 schema:givenName Nathalie
    16 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250741512.98
    17 schema:sdDatePublished 2022-11-24T21:37
    18 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    19 schema:sdPublisher N65c2287bfcd143baa87df7fb3c205e9d
    20 sgo:license sg:explorer/license/
    21 sgo:sdDataset persons
    22 rdf:type schema:Person
    23 N1946e8c0ade64daca38783683d6ee6c4 schema:affiliation grid-institutes:grid.413852.9
    24 sgo:isCurrent true
    25 rdf:type schema:OrganizationRole
    26 N65c2287bfcd143baa87df7fb3c205e9d schema:name Springer Nature - SN SciGraph project
    27 rdf:type schema:Organization
    28 grid-institutes:grid.239546.f schema:Organization
    29 grid-institutes:grid.25697.3f schema:Organization
    30 grid-institutes:grid.411430.3 schema:Organization
    31 grid-institutes:grid.413306.3 schema:Organization
    32 grid-institutes:grid.413852.9 schema:Organization
    33 grid-institutes:grid.413858.3 schema:Organization
    34 grid-institutes:grid.413945.e schema:Organization
    35 grid-institutes:grid.413959.3 schema:Organization
    36 grid-institutes:grid.414103.3 schema:Organization
    37 grid-institutes:grid.42505.36 schema:Organization
    38 grid-institutes:grid.452431.5 schema:Organization
    39 grid-institutes:grid.462854.9 schema:Organization
    40 grid-institutes:grid.7849.2 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...